

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number  
**WO 01/21790 A1**

(51) International Patent Classification<sup>2</sup>: C12N 15/12,  
15/54, 5/10 // A61K 48/00, 35/30

(74) Agent: GILL JENNINGS & EVERY: Broadgate House,  
7 Eldon Street, London EC2M 7LH (GB).

(21) International Application Number: PCT/GB00/03588

(81) Designated States (*national*): AE, AG, AI, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(22) International Filing Date:  
18 September 2000 (18.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
99307405.3 17 September 1999 (17.09.1999) EP

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants: RENEURON LIMITED [GB/GB]: Euro-  
point Centre, 5-11 Lavington Street, London SE1 0NZ  
(GB), LUDWIG INSTITUTE FOR CANCER RE-  
SEARCH [GB/GB]: Imperial College School of Medicine  
at St. Mary's, Norfolk Place, Paddington, London W2  
1PG (GB).

**Published:**

— With international search report.

(72) Inventor: JAT, Parmjit; Ludwig Institute for Cancer Re-  
search, Glen House, Stag Place, London SW1E 5AG (GB).

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: CONDITIONAL IMMORTALISATION OF CELLS

(57) Abstract: A recombinant, or genetically engineered, mammalian cell, comprises a conditionally-inducible oncogene and an exogenous polynucleotide encoding the catalytic sub-unit of the telomerase complex. The recombinant cells are useful in therapy, to replace lost or damaged cells.

WO 01/21790 A1



## CONDITIONAL IMMORTALISATION OF CELLS

Field of the Invention

The present invention relates to the immortalisation of mammalian cells for therapeutic application.

5 Background to the Invention

There is a growing awareness and understanding of the importance of transplantation therapy to treat damage to tissues and organs. While organ transplantation is widely practiced, therapies based on the transplantation of  
10 individual cells are still in a relatively early phase of clinical development.

For example, there is growing recognition that the transplantation of suitable cells into a damaged brain may improve or correct any sensory, motor, behavioural or  
15 psychological deficits caused by the damage.

For cell-based therapies to be useful, it must be possible to obtain sufficient cells for transplantation. One means for ensuring this is to culture undifferentiated cells under conditions which allow repeated cell division  
20 and growth. One difficulty with using undifferentiated cells is that unregulated cell division must be switched off either prior to or on transplantation into the patient, to prevent uncontrolled growth at the site of transplantation.

Many different techniques have been developed to provide suitable cells for transplantation. With regard to neural transplantation, one approach has been to maintain undifferentiated foetal cells under culture conditions that permit cell division to occur, and to subsequently induce  
30 differentiation *in vitro*, prior to transplantation.

Reynolds and Weiss, Science, 1992;255:1707, disclose the use of epidermal growth factor (EGF) to induce the *in vitro* proliferation of adult mouse brain cells. Under suitable conditions it was thought that the cells could be  
35 induced to differentiate into astrocytes and neurons.

International Patent Application No. WO-A-94/16059 discloses a technique for maintaining a primary neuronal

cell culture *in vitro* by culturing the cells in a serum-free media supplemented with at least one trophic factor.

International Patent Application No. WO-A-97/10329 discloses an alternative technique, using a conditionally-immortalised cell line. This cell line comprises an immortalising temperature-sensitive oncogene which, under permissive conditions, maintains neuroepithelial stem cells in the undifferentiated state. Upon transplantation the oncogene is switched off due to the higher temperature of the human body (37°C) and the cells differentiate into the cell types required to repair damage. The advantage of using the oncogene is that the cells are maintained in the undifferentiated state until transplantation, at which point the cells differentiate, in response to the specific damage, into the phenotype of the damaged or lost cells. US 5688692 also discloses cells expressing a non-DNA binding, temperature-sensitive T antigen.

However, it is recognised that although human cells expressing oncogenes can have an extended life, they still stop dividing and eventually undergo crisis (cell death).

It has also been proposed that human cells can be immortalised by reconstituting telomerase activity BY incorporating an exogenous copy of the catalytic subunit of human telomerase (Bodnar et al, Science, 1998; 279: 249-252). Telomerase acts to maintain telomeres found at the ends of chromosomes, and it is believed that the gradual shortening of telomeres during cell duplication contributes to senescence and that therefore reconstituting telomerase immortalises cells. Human telomerase has now been used to immortalise many different cell types.

Counter et al., PNAS (USA), 1998; 95(25):4723-14728, also discloses that ectopic expression of the telomerase catalytic subunit (hTERT) can allow post senescent cells to proliferate beyond crisis to cellular immortality. The cells studied were transformed with an oncogene expressing SV40 T-antigen. However, the authors conclude that hTERT expression alone may suffice to immortalise cells, and that

activation of hTERT may be a critical step in tumour progression. Therefore, the general teaching of this publication is that hTERT transformed cells would be immortal. This means that the cells would be unsuitable for use in transplantation therapy.

Therefore, while many of the techniques disclosed above may be useful, there is still a need for methods to obtain cells which retain immortality prior to transplantation, but which lose immortality on transplantation.

#### Summary of the Invention

The present invention is based on the realisation that cells transduced with a conditionally-inducible oncogene and at least the catalytic subunit of the telomerase complex are immortal under permissive conditions but lose immortality under non-permissive conditions.

According to one aspect of the present invention, a recombinant, or genetically engineered, mammalian cell comprises a conditionally-inducible or temperature-sensitive oncogene, and an exogenous polynucleotide encoding at least the catalytic sub-unit of the telomerase complex.

According to a second aspect of the invention, a recombinant polynucleotide construct comprises a gene that encodes at least the catalytic sub-unit of the telomerase complex, and a conditionally-inducible or temperature-sensitive oncogene.

According to a third aspect, a method for immortalising a mammalian cell comprises incorporating, within a proliferating mammalian cell, a conditionally-inducible oncogene and an exogenous polynucleotide encoding the catalytic sub-unit of the telomerase gene.

According to a fourth aspect, the cells of the present invention may be used in therapy, in particular in the manufacture of a medicament for the treatment of a disease associated with cell loss or damage. For example,

neuroepithelial stem cells may be used for the treatment of disorders associated with brain damage e.g. Alzheimers.

It has been found that cells according to the present invention retain a high level of stability and at non-permissive temperatures are not immortal.

This is a surprising and important finding as it would be expected, based on the prior art, for the cells to remain immortal, due to the reconstitution of the telomerase activity. However, it appears that, although the gene encoding the telomerase is constitutive, the telomerase does not act to retain immortality. The retention of conditionality and increased stability, makes the cells of the present invention suitable to be passaged serially to derive a cell line for transplantation.

#### Description of the Drawings

The following figures illustrate the invention.

Figure 1 is a schematic illustration of a polynucleotide construct containing both the hTERT and the temperature-sensitive oncogene encoding the SV40 large T-antigen; and

Figure 2 is a schematic illustration of an alternative construct with the hTERT and oncogene in a different order from that in Figure 1.

#### Description of the Invention

The present invention discloses methods for preparing cells which are suitable for transplantation therapy and which are immortal up to the time of transplantation.

The cells require a conditionally-inducible oncogene to be present. The term "conditionally-inducible" is used herein to refer to oncogenes, the expression of which can be regulated under certain conditions. The oncogene will undergo expression when so-called permissive conditions are applied. For example, some oncogenes are temperature-sensitive and are only expressed when the temperature of their environment is below a certain value. In one embodiment of the invention, the oncogene that is used is a non-DNA binding, temperature-sensitive, mutant of the SV-

40 large T-antigen gene (U19tsA58). Suitable alternatives are also known and include the oncogene of the polyoma T-antigen.

5 The cells also require an exogenous polynucleotide that encodes at least the catalytic sub-unit of the telomerase complex. The term "exogenous" is used herein in its normal context to refer to the polynucleotide introduced into the cell, and distinguish from naturally-occurring endogenous polynucleotides. The catalytic sub-  
10 unit of the telomerase complex is an enzyme that acts like a reverse transcriptase, and is known in the art. The human sub-unit is disclosed in GB-A-2317891.

The oncogene and the polynucleotide encoding the telomerase may be comprised in a recombinant DNA or  
15 retroviral vector or construct to transduce/infect the cells. The two components may be incorporated into one vector or each may be comprised in a separate vector. The vectors or constructs of the invention may further comprise a suitable promoter region to initiate transcription of DNA and a selectable marker which may be used to identify those  
20 cells that have undergone transduction/infection. Regulation of expression may be carried out by methods known to the skilled person. For example, regulation may be effected using the long terminal repeat (LTR) promoter. Alternative promoters will be apparent to the skilled  
25 person. For example, regulation may be effected using the cytomegalovirus (CMV) promoter. The CMV promoter is a very strong promoter, and may be preferred when the cells are neural cells, e.g. neuroepithelial stem cells.

30 Methods for introducing suitable constructs into cells, are known to the skilled person.

Any mammalian cell may be used in the present invention.

For example, the cell may be an endothelial cell, and  
35 may be used for the revascularisation of the leg, heart and other organs. Preferably, the cell is a human somatic cell, e.g. human epithelial stem cell, which is capable of

differentiation into a specific cell type. A particularly preferred cell is a human neuroepithelial stem cell which may be used in neural transplantation to repair cell loss or damage and correct behavioural or psychological deficits. Alternatively, the cell may be a differentiated cell, e.g. the  $\beta$  cells of Islets of Langerhans. Additional cells may include but are not limited to those obtainable from the endocrine glands, retinal cells, cochlear cells, liver cells, osteoblast and osteoclasts, myoblasts and keratinocytes.

Preferably, the oncogene and the telomerase are incorporated into the cell during the early culture phase, usually within the first 10 cell divisions. The order of incorporating the oncogene and telomerase is not critical to the success of the method, although it is preferred that the telomerase is introduced first. This is because it has been found, surprisingly, that introducing the telomerase first provides better assurance for achieving a diploid cell line.

The transduced or infected cells may be cultured under conditions known to those skilled in the art. It is preferable that the cells are cultured under non-stressed conditions. A skilled person will appreciate the conditions suitable for each particular cell type, based on conventional culture techniques.

The invention will now be described further in the following Examples with reference to the drawings. The Examples show that by transducing suitable human cells with a temperature-sensitive oncogene and the catalytic sub-unit of the telomerase complex, it is possible to retain stability as the cell cultures are passaged in a suitable culture medium.

#### Example 1

1. Isolation of mammary interlobular fibroblasts (HMF) and mammary microvascular endothelial (MMVE) cells:

Cultures of mammary interlobular fibroblasts and mammary microvascular endothelial cells were prepared from

normal breast tissue, obtained with consent from patients undergoing cosmetic surgery (reduction mammoplasty). Cultures of interlobular fibroblasts were prepared as described in Atherton et al, J. Cell Sci., 107:2931-2939, and maintained with Dulbecco's Modified Eagles medium (DMEM) supplemented with 10% fetal calf serum and antibiotics (penicillin/streptomycin). Endothelial cells from microvessels were isolated by immunomagnetic sorting of primary cultures, using the QBEND-40 mouse monoclonal antibody against thrombomodulin, essentially as described by Drake & Lock, Human Reprod., 1992; 6:1156-1159. Endothelial cultures were established and maintained in EGM-2 medium (Biowhittaker).

2. In vitro culture of cells to senescence.

As a control, preparations of cells were cultured to determine the point of senescence. The cells were found to have a culture lifespan of between 10-16 population doublings when cultured in EGM-2. Apart from an accumulation of granular particles in the cytoplasm, the senescent cells otherwise resembled their early-passage counterparts, differing only in the complete absence of mitosis.

3. Transduction of tsA58-U19 and extended growth to crisis.

Cell preparations from different individual donors were transduced, while still proliferating at between populations doublings 6-9, with the tsA58-U19 (Almazan and McKay, Brain Res., 1992; 579(s):234-245) double recombinant mutant of the SV-40 T-antigen gene in the pZIP vector containing the neo-r gene. Transduction was carried out using a helper virus-free amphotropic retroviral packaging system (PA317, Clone 8) as described in Stamps et al., Int. J. Cancer, 1994; 57(6):865-874. Polybrene at 8 ug/ml was used as an adjuvant to improve virus uptake.

Transduction frequencies varied between 10-25% after selection with geneticin at 0.25 mg/ml. After transfer to the permissive temperature for tsA58 (33.5°C) these



cultures were passaged further for between 33 and 56 population doublings at a split ratio of 1:4. During this time all cells remained stringently temperature-sensitive with little or no growth at 36.5°C and above. In all cases, however, growth eventually ceased with the appearance of abnormal mitosis and abnormal cell morphologies including size and nuclear heterogeneity, indicative of crisis. A total of not less than 10<sup>8</sup> cells in total have been passaged to crisis, without a single instance of 'spontaneous' immortalisation being observed. This is in contrast to mammary epithelial cells, which repeatedly immortalise at a frequency of approximately 1 in 5 x 10<sup>6</sup> cells maintained to crisis.

4. Transduction of h-TERT and subsequent immortalisation with retention of conditional growth.

Early-passaged cells from one donor transduced with the ts T antigen system (MMVE-2) were further transduced with the full-length cDNA copy of the catalytic sub-unit of the human telomerase gene in the pBabe vector (Morgenstern and Land, Nucleic Acids Research, 1990; 18:3587-3596) together with a hygromycin B-resistance gene, using a human amphotropic packaging system (TE-FLY). A series of four cloned packaging lines were used, having been selected previously for highest titres on the basis of transfer of hygromycin resistance to a target human cell line (EJ bladder carcinoma cells). Each was used to transduce, in duplicate, the MMVE-2 ts T cells in the presence of 8 µg/ml polybrene. Successful transduction was observed after selection with 25 µg/ml hygromycin B.

Surprisingly, the transduced cells appeared to overcome senescence, and continued to proliferate at 33.5°C, without any overt crisis or change in proliferation rates, for over 40 weeks. The cells have so far undergone >100 population doublings at a constant rate, and appear to be functionally immortal.

When tested for temperature sensitivity by replicate culture at 33.5, 36.5 and 39.5°C, the hTERT transduced

MMVE-2 tsT cells were, surprisingly, as sensitive as early passaged tsT only cells. Contrary to what might be expected, there was little growth at 36.5°C and none at 39.5°C, i.e. the cells were conditionally immortal. All

5 cultures were carried out with the EGM-2 medium which contains a variety of endothelial-specific growth factors, including b-FGF, VEGF, IGF-2 and heparin, as well as 2% FCS, thus avoiding the testing of cells under sub-optimal or 'stressed' growth conditions.

10 To determine the extent to which temperature-induced growth arrest was irreversible, the fibroblast cultures were analysed using a clonogenic assay in which the colony forming efficiency (CE) was determined under optimal conditions (5% oxygen at 33.5°C), after different periods

15 of growth arrest at 39.5°C. There was a substantial reduction in CE in most cultures which was proportional to the time at the non-permissive temperature. In one of the HMF cultures, for example, the CE after 14 days at 39.5°C had dropped to <5% of control value, with most colonies

20 being small and abortive. The results demonstrate the progressive irreversibility of the transduced cells and show that this is due to the thermal inactivation of T-antigen rather than a non-specific effect of heat shock.

The cells were also tested to establish whether they

25 undergo biochemical senescence upon inactivation of T antigen, by staining cultures for senescence-activated acid  $\beta$ -galactosidase. After 4-8 days at 39.5°C all the fibroblast cultures showed varying numbers of positive cells (1-10%), whereas no positive cells were detected in

30 corresponding cultures at 33.5°C (<0.1%). This compares with a crises culture of T-antigen only HMF fibroblasts where 53% of the cells were positive. This demonstrates that the immortalised cells are dependent upon T-antigen to maintain growth, and that inactivation of T-antigen causes

35 irreversible cessation of cell growth, and entry into senescence.

The cell cultures were also karyotyped to determine whether the order and timing of retroviral gene transduction affected the chromosomal status of the resulting cells. A diploid or near-diploid modal number of chromosomes (46) was observed in both MMVE and HMF cells; derived by introducing both genes during the early phase (i.e. within the first 10 cell divisions) with hTERT first. When both genes were introduced during the early phase with the oncogene first, the cells were shown to have a bimodal karyotype with near diploid and near tetraploid modes. This is a surprising finding and demonstrates that diploid cells can be prepared more effectively by choosing to insert the catalytic subunit of telomerase first into the cell.

In summary, the results obtained show, surprising, that cells comprising the full-length gene encoding the telomerase catalytic sub-unit and the temperature-sensitive oncogene, remain conditional for growth, i.e. the cells are not immortal at high temperature.

The above results demonstrate that separate transduction with a temperature-sensitive oncogene and a catalytic telomerase subunit, can exhibit improved characteristics compared to cells comprising only the temperature-sensitive oncogene.

Although separate transduction shows good results, it may be easier to construct a suitable vector having both the oncogene and the gene encoding the telomerase.

#### Example 2

This Example demonstrates the production of suitable expression vectors co-expressing thermolabile T-antigen derived from the non-DNA binding mutant of the SV40 early region (U19tsA58); the catalytic sub-unit hTERT of the telomerase complex (cDNA) (Counter et al., PNAS, 1998; 95(25):14723-14728); and a dominantly-acting selectable neomycin phosphotransferase resistant marker (Neo) which encodes resistance to G418 (Clontech). The final construct was assembled in the high titre Moloney murine leukaemia

virus (Mo MuLV) based retroviral expression vector, pBabe (Morgenstern and Land, *Supra*). The retrovirus lifecycle was used to convert the SV40 early region into viruses that make only the large T antigen. All constructs were assembled in a rec A-host (JS4-rec A-derivative of MC1061) using ampicillin selection.

Two versions of the vector were constructed:

#### Construct 1

This construct is illustrated in Fig. 1. Mo MuLV LTR was used to drive hTERT, and the SV40 early promoter is used to drive both U19tsA58 and Neo. An internal ribosome entry site (IRES) was integrated between the U19tsA58 and Neo genes (fused in frame to the Neo gene) to induce reinitiation of translation by eukaryotic ribosomes.

#### Construct 2

This construct is illustrated in Fig 2. Mo MuLV LTR was used to drive U19tsA58, and the SV40 early promoter is used to drive hTERT and Neo. An IRES sequence was inserted between hTERT and Neo.

#### Cloning strategy

Each vector was assembled in three sections. The vectors pBabe Neo-hTERT (hTERT excised from pCI-Neo-hTERT, provided by R.A. Weinberg, Whitehead Institute), and pBabe-Neo-U19tsA58 (where U19tsA58 is inserted in the sense orientation in respect to retrovirus transcription) were used to prepare the front-end of constructs 1 and 2, respectively.

The cloning of the IRES and its fusion in frame to the Neo gene was performed in the cloning vector pPolyIII-I (obtained from D. Kioussis, MRC, Mill Hill). pPolyIII-I is a useful vector for constructing gene sequences as it contains a large polylinker comprising many sites for restriction enzymes recognising a 6 nucleotide sequence. The third component was cloned from the vector pBabe Puro (pBabe with a puromycin resistance gene).

#### Construct 1

##### A. Cloning of IRES:Neo

The Neo sequence was amplified by PCR from the pLXSN (Clontech) vector. To keep the total length of the construct to a minimum, only the Neo coding region (2066bp-2860bp of pLXSN) was used. The 586bp IRES (encephalomyocarditis virus (EMC) RNA 5' non-coding region) is available from the Novogen vector pCITE-1. The initiation region of EMC has a *Bal* I cloning site at position 2918 and an *Nco* I site at 2925 of pCITE-1, which can be used to insert the foreign sequence in frame.

It is recommended that foreign sequences lacking their own AUG are fused in frame to the viral AUG at 2915-2917, however cutting with *Bal* I produces a G at the beginning of the first codon after the AUG of the foreign sequence. This is incompatible with the Neo sequence where the first base after the AUG is A. To overcome this problem, the 5' Neo primer used to amplify the Neo sequence from pLXSN, was designed to recreate the IRES sequence between bases 2918 and 2929.

Forward Neo primer (SEQ ID NO. 1)

5' ...CC ACA ACC ATG ATT GAA CAA GAT G ...3'

3' IRES  
sequence

5' Neo sequence

To insert the 3' end of the Neo sequence into pPolyIII-I, the 3' PCR primer was designed to include a *Sal* I site and a *Cla* I site (for cloning from pPolyIII-I into pBabe).

Reverse Neo primer (SEQ ID NO. 2)

5' ...CCG TCG ACA TCG ATT CAG AAG AAC TCG TCA AG ...3'

*Sal* I

*Cla* I

3' neo sequence

It was therefore possible to cut the IRES from pCITE-1 with *Eco* RI and *Bal* I (isoschizomers are *Mls* I, *Msc* I) and ligate the sequence into the *Eco* RI and *Bal* I sites of pPolyIII-I. The Neo sequence was then amplified from the

5 vector pLXSN using the previously mentioned forward and reverse Neo primers and the 3' region of the PCR product cut with *Sal* I prior to ligation into the *Bal* I and *Sal* I sites of pPolyIII-I-IRES.

B. Insertion of U19tsA58

10 U19tsA58 was excised from pZip-U19tsA58, (provided by P. Jat of Ludwig Institute for Cancer Research) by a *Bam* HI digest and inserted into the *Bam* HI site of pPolyIII-I-IRES:Neo in the sense orientation in respect to retrovirus transcription.

15 C. Final construct

The final construct was created by the three part ligation of:

(i) U19tsA58-IRES-Neo excised from pPolyIII-I-U19tsA58-IRES:Neo by *Sfi* I *Cla* I digest;

20 (ii) the front of the construct provided from the vector pBabe-Neo-hTERT, by digestion with *Sfi* I and *Not* I. Left hand section required; and

(iii) pBS ori-containing fragment, acquired from the vector pBabe-Puro, by digestion with *Cla* I and *Not* I.

25 Right hand side of vector required.

The final construct is as shown in Figure 1.

Construct 2

A. pPolyIII-I-hTERT-IRES:Neo

To clone the hTERT cDNA and IRES:Neo into pPolyIII-I, pBabe Neo-hTERT was digested initially with *Sal* I, which cuts at the 3' end of hTERT. The cloning sites of hTERT are *Eco* RI (5') and *Sal* I (3'), however hTERT cannot be cloned into the *Sal* I site of pPolyIII-I as this is the cloning site for the 3' end of IRES:Neo. Therefore the

35 hTERT sequence was first blunt-ended prior to excision of the cDNA sequence from pBabe Neo-hTERT with *Eco* RI. pPolyIII-I-IRES:Neo was cut with *Eco* RI, blunted and cut

with *Sal* I to excise the IRES:Neo. hTERT and IRES:Neo were then cloned into the *Eco* RI and *Sal* I sites of pPolyIII-I joining at a blunt end ligation between 3' hTERT and 5' IRES:Neo.

5       The assembly of construct 2 involved a three part ligation of:

      (i) hTERT-IRES:Neo excised from pPolyIII-I-IRES:Neo at the *Sfi* I and *Cla* I sites;

10       (ii) the left-hand side of construct 2, acquired from the vector pBabe-Neo-U19tsA58, by digestion with *Sfi* I and *Not* I; and

      (iii) the right-hand side of construct 2, acquired from the vector pBabe-Puro by digestion with *Cla* I and *Not* I.

15       The final construct is as shown in Figure 2.

      With regard to the design of the constructs, it may be more desirable to regulate expression of both the oncogene and hTERT components from the CMV promoter. This could be done by linking the components using an IRES sequence with insertion downstream of a CMV promoter, in a retroviral vector.

      The constructs may be used to transduce suitable cells to produce conditionally-immortalised cells that have improved stability during passaging.

25       The recombinant cells of the invention may have use in therapy. Methods for the preparation of formulations for delivery to a patient will be apparent to the skilled person. Suitable excipients, diluents etc, will again be apparent based on current practice in preparing cell-based therapies. The amount of cells required for delivery will vary depending on the form of treatment, the severity of the disease/damage, and the need for applying multiple doses over a treatment period. However, the skilled person can readily determine the appropriate treatment based on

30       existing cell transplantation therapies.

35

CLAIMS

1. A mammalian cell, comprising a conditionally-inducible oncogene and an exogenous polynucleotide encoding the catalytic sub-unit of the telomerase complex.
- 5 2. A cell according to claim 1, wherein the oncogene and the exogenous polynucleotide are comprised in a recombinant vector.
3. A cell according to claim 1 or claim 2, wherein the oncogene is temperature-sensitive.
- 10 4. A cell according to any preceding claim, which is a human somatic cell.
5. A cell according to any preceding claim, which is a mammalian stromal fibroblast cell or a mammalian microvascular cell.
- 15 6. A cell according to any of claims 1 to 4, which is a human stem cell.
7. A cell according to claim 6, which is a neuroepithelial stem cell.
8. A cell according to any preceding claim, wherein the
- 20 oncogene comprises the temperature-sensitive mutant of the SV-40 T-antigen gene.
9. A cell according to claim 8, wherein the mutant is tsA58-U19.
10. A recombinant polynucleotide that encodes the
- 25 catalytic sub-unit of the telomerase complex and a conditionally-inducible oncogene.
11. A polynucleotide according to claim 10, further comprising a selectable marker gene and a promoter region.
12. A method for immortalising a mammalian cell,
- 30 comprising incorporating within a proliferating cell a conditionally-inducible oncogene and an exogenous polynucleotide encoding the catalytic sub-unit of the telomerase complex.
13. A method according to claim 12, wherein the oncogene
- 35 and exogenous polynucleotide are incorporated into the cell within the first 10 cell divisions.



14. A method according to claim 12 or claim 13, wherein the exogenous polynucleotide is introduced into the cell before the oncogene.

5 15. Use of a cell according to any of claims 1 to 9, in the manufacture of a medicament for the treatment of a disease associated with cell loss or damage.

16. Use according to claim 15, wherein the cell is a neuroepithelial stem cell.

Fig. 1.





Fig. 2.



## SEQUENCE LISTING

<110> ReNeuron Limited  
Ludwig Institute for Cancer Research

<120> CONDITIONAL IMMORTALISATION OF CELLS

<130> REP06053WO

<140> (not yet known)

<141> 2000-09-18

<150> 99307405.3

<151> 1999-09-17

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide

<400> 1  
ccacaaccat gattgaacaa gatg 24

<210> 2

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide

<400> 2  
ccgtcgacat cgattcagaa gaactcgtca ag 32

## INTERNATIONAL SEARCH REPORT

Internat. Application No.  
PCT/GB 00/03588

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N15/54 C12N5/10 //A61K48/00,A61K35/30

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 10329 A (INST OF PSYCHIATRY ;SINDEN JOHN (GB); GRAY JEFFREY ALAN (GB); HODG) 20 March 1997 (1997-03-20) cited in the application the whole document	1-11
Y	COUNTER C.M. ET AL.: "Dissociation among in vitro telomerase activity, telomere maintenance and cellular immortalization" PROC. NATL. ACAD. SCI. USA, vol. 95, December 1998 (1998-12), pages 14723-14728, XP002130650 cited in the application the whole document	1-11
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claims or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

11 December 2000

Date of mailing of the international search report

18/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2200 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Galli, I

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 00/03588

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HAHN W.C. ET AL.: "Creation of human tumour cells with defined genetic elements" NATURE, vol. 400, 27 July 1999 (1999-07-27), pages 464-468, XP002130651 the whole document	1-11
A	WO 98 37181 A (COUNTER CHRISTOPHER M ;WEINBERG ROBERT A (US); WHITEHEAD BIOMEDICA) 27 August 1998 (1998-08-27) page 17, line 19 -page 18, line 9	1-11

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/03588

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9710329 A	20-03-1997	AU 711563 B	14-10-1999
		AU 6937596 A	01-04-1997
		CA 2231436 A	20-03-1997
		CN 1193345 A	16-09-1998
		CZ 9800558 A	17-06-1998
		EP 0850298 A	01-07-1998
		HU 9802091 A	28-12-1998
		JP 11513242 T	16-11-1999
		NO 981072 A	12-05-1998
		PL 325646 A	03-08-1998
		SK 30698 A	11-01-1999
WO 9837181 A	27-08-1998	NONE	